BAJAJ BROKING
The US FDA has restricted imports of 11 Viatris drugs made in India, citing violations of federal regulations. Exceptions apply to four drugs due to shortage concerns. Viatris is addressing these issues with a comprehensive remediation plan.
The United States Food and Drug Administration (US FDA) has issued a warning letter to Viatris regarding its drug manufacturing facility in Indore, Madhya Pradesh. Following an inspection, the agency identified violations of federal requirements, leading to the restriction of imports for 11 products manufactured at the facility. The impacted drugs, primarily oral finished doses like tablets and capsules, will not be accepted into the United States until the warning letter is resolved.
Also read: Adani Defence Acquires 85.8% Stake in Air Works for ₹400 Crore
Action: US FDA restricted imports of 11 Viatris products.
Reason: Federal violations identified at the Indore facility.
Exceptions: Four drugs allowed conditionally due to shortages.
Remediation: Viatris implemented corrective actions and engaged independent experts.
Also read: TVS Motor Acquires Majority Stake in DriveX with 87.38% Holding
The 11 restricted products, whose specifics have not been disclosed, are key oral medications catering to therapeutic areas such as antibacterials, diabetes management, and cardiovascular health. The restriction poses challenges for Viatris, formed through the merger of Mylan and Pfizer's off-patent drug business. The company operates four manufacturing sites in India, which play a vital role in its global supply chain.
To address potential shortages, the US FDA has granted conditional exceptions for four products, allowing them to be imported. Additional exceptions may be considered after further discussions.
In response to the warning letter, Viatris has committed to submitting a detailed plan within the required time frame. The company has implemented corrective and preventive actions at the Indore facility, supported by independent third-party experts.
The following table summarises the key details:
Aspect | Details |
Facility Location | Indore, Madhya Pradesh, India |
Restricted Products | 11 oral finished doses (tablets, capsules) |
Conditional Exceptions | 4 products due to shortage concerns |
Therapeutic Categories | Antibacterials, diabetes, cardiovascular therapies |
The import restrictions highlight regulatory scrutiny in pharmaceutical manufacturing. As Viatris works on resolving these issues, its stock performance may be impacted. Monitoring the Mylan share price and Pfizer share price could provide insights into investor sentiment as the company remediates its compliance concerns.
The US FDA’s import restrictions on Viatris drugs underscore the importance of compliance with manufacturing regulations. While the company addresses the violations, conditional exceptions for some drugs may mitigate the immediate impact.
Also read: BEL Secures Orders Worth ₹973 Crore, Achieves 40% of FY25 Target
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading